AustralieFrV1, Ncbi, Curation, bibRecord, 004015

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Identifieur interne : 004015 ( Ncbi/Curation ); précédent : 004014; suivant : 004016

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Auteurs : Sultan Linjawi [Australie] ; Bruce W. Bode [États-Unis] ; Louis B. Chaykin [États-Unis] ; Jean-Pierre Courrèges [France] ; Yehuda Handelsman [États-Unis] ; Lucine M. Lehmann [Danemark] ; Abhishek Mishra [Inde] ; Richard W. Simpson

Source :

Diabetes Therapy [ 1869-6953 ] ; 2016.

RBID : PMC:5306117

Abstract

Introduction

The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs.

Methods

In this 26-week open-label phase 3b trial, patients on maximum-dose GLP-1RA therapy (liraglutide once daily or exenatide twice daily) with metformin alone or with pioglitazone and/or sulfonylurea were randomized 2:1 to IDegLira once daily (n = 292) or to unchanged GLP-1RA therapy (n = 146), continuing OADs at the pre-trial dose.

Results

After 26 weeks, HbA_1c reductions were superior with IDegLira versus unchanged GLP-1RA; estimated treatment difference −0.94% (−10.3 mmol/mol), p < 0.001. Mean HbA_1c reduced from 7.8% to 6.4% (61.5 to 46.9 mmol/mol) with IDegLira and from 7.7 to 7.4% (60.8 to 57.1 mmol/mol) with unchanged GLP-1RA. With IDegLira, 75% and 63% of patients achieved HbA_1c <7% and ≤6.5%, compared with 36% and 23% on unchanged GLP-1RA, respectively. Fasting plasma glucose and 9-point self-monitored blood glucose profiles improved significantly more with IDegLira versus unchanged GLP-1RA. The mean change in weight was +2.0 kg with IDegLira, versus −0.8 kg with unchanged GLP-1RA. Rates of confirmed hypoglycemia were low, but higher with IDegLira versus unchanged GLP-1RA. The safety profile of IDegLira was consistent with previous findings; both treatments were well tolerated and the rate of nausea was low in both groups. IDegLira improved patient-reported outcomes versus unchanged GLP-1RA.

Conclusions

IDegLira provided superior glycemic control versus unchanged GLP-1RA and represents an efficacious intensification approach in patients inadequately controlled on GLP-1RAs.

Trial registration

ClinicalTrials.gov #NCT01676116.

Funding

Novo Nordisk.

Electronic supplementary material

The online version of this article (doi:10.1007/s13300-016-0218-3) contains supplementary material, which is available to authorized users.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306117

DOI: 10.1007/s13300-016-0218-3
PubMed: 27943107
PubMed Central: 5306117

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B74
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B51
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000564
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001101
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001098
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001098
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004015

Links to Exploration step

PMC:5306117

Curation

No country items

Richard W. Simpson

<affiliation><nlm:aff id="Aff8"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id>
<institution-id institution-id-type="GRID">grid.1002.3</institution-id>
<institution></institution>
<institution>Monash University and Eastern Health,</institution>
</institution-wrap>
Box Hill, VIC Australia</nlm:aff>
<wicri:noCountry code="subfield">VIC Australia</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial</title>
<author><name sortKey="Linjawi, Sultan" sort="Linjawi, Sultan" uniqKey="Linjawi S" first="Sultan" last="Linjawi">Sultan Linjawi</name>
<affiliation wicri:level="2"><nlm:aff id="Aff1">Coffs Endocrine & Diabetes Services, Coffs Harbour, NSW Australia</nlm:aff>
<country>Australie</country>
<placeName><region type="state">Nouvelle-Galles du Sud</region>
</placeName>
<wicri:cityArea>Coffs Endocrine & Diabetes Services, Coffs Harbour</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bode, Bruce W" sort="Bode, Bruce W" uniqKey="Bode B" first="Bruce W." last="Bode">Bruce W. Bode</name>
<affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.427536.1</institution-id>
<institution></institution>
<institution>Atlanta Diabetes Associates,</institution>
</institution-wrap>
Atlanta, GA USA</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
<wicri:cityArea>Atlanta</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chaykin, Louis B" sort="Chaykin, Louis B" uniqKey="Chaykin L" first="Louis B." last="Chaykin">Louis B. Chaykin</name>
<affiliation wicri:level="2"><nlm:aff id="Aff3">Meridien Research, Bradenton, FL USA</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Meridien Research, Bradenton</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Courreges, Jean Pierre" sort="Courreges, Jean Pierre" uniqKey="Courreges J" first="Jean-Pierre" last="Courrèges">Jean-Pierre Courrèges</name>
<affiliation wicri:level="3"><nlm:aff id="Aff4">Diabetology and Vascular Disease Unit, General Hospital, Narbonne, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Diabetology and Vascular Disease Unit, General Hospital, Narbonne</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Narbonne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Handelsman, Yehuda" sort="Handelsman, Yehuda" uniqKey="Handelsman Y" first="Yehuda" last="Handelsman">Yehuda Handelsman</name>
<affiliation wicri:level="2"><nlm:aff id="Aff5">Metabolic Institute of America, Tarzana, CA USA</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Metabolic Institute of America, Tarzana</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lehmann, Lucine M" sort="Lehmann, Lucine M" uniqKey="Lehmann L" first="Lucine M." last="Lehmann">Lucine M. Lehmann</name>
<affiliation wicri:level="1"><nlm:aff id="Aff6"><institution-wrap><institution-id institution-id-type="GRID">grid.425956.9</institution-id>
<institution></institution>
<institution>Novo Nordisk A/S,</institution>
</institution-wrap>
Søborg, Denmark</nlm:aff>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Søborg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mishra, Abhishek" sort="Mishra, Abhishek" uniqKey="Mishra A" first="Abhishek" last="Mishra">Abhishek Mishra</name>
<affiliation wicri:level="1"><nlm:aff id="Aff7">Novo Nordisk, Bangalore, India</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Novo Nordisk, Bangalore</wicri:regionArea>
<wicri:noRegion>Bangalore</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Simpson, Richard W" sort="Simpson, Richard W" uniqKey="Simpson R" first="Richard W." last="Simpson">Richard W. Simpson</name>
<affiliation><nlm:aff id="Aff8"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id>
<institution-id institution-id-type="GRID">grid.1002.3</institution-id>
<institution></institution>
<institution>Monash University and Eastern Health,</institution>
</institution-wrap>
Box Hill, VIC Australia</nlm:aff>
<wicri:noCountry code="subfield">VIC Australia</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27943107</idno>
<idno type="pmc">5306117</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306117</idno>
<idno type="RBID">PMC:5306117</idno>
<idno type="doi">10.1007/s13300-016-0218-3</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000B74</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B74</idno>
<idno type="wicri:Area/Pmc/Curation">000B51</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000B51</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000564</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000564</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001101</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001101</idno>
<idno type="wicri:Area/PubMed/Curation">001098</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001098</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001098</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001098</idno>
<idno type="wicri:Area/Ncbi/Merge">004015</idno>
<idno type="wicri:Area/Ncbi/Curation">004015</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial</title>
<author><name sortKey="Linjawi, Sultan" sort="Linjawi, Sultan" uniqKey="Linjawi S" first="Sultan" last="Linjawi">Sultan Linjawi</name>
<affiliation wicri:level="2"><nlm:aff id="Aff1">Coffs Endocrine & Diabetes Services, Coffs Harbour, NSW Australia</nlm:aff>
<country>Australie</country>
<placeName><region type="state">Nouvelle-Galles du Sud</region>
</placeName>
<wicri:cityArea>Coffs Endocrine & Diabetes Services, Coffs Harbour</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bode, Bruce W" sort="Bode, Bruce W" uniqKey="Bode B" first="Bruce W." last="Bode">Bruce W. Bode</name>
<affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.427536.1</institution-id>
<institution></institution>
<institution>Atlanta Diabetes Associates,</institution>
</institution-wrap>
Atlanta, GA USA</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
<wicri:cityArea>Atlanta</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chaykin, Louis B" sort="Chaykin, Louis B" uniqKey="Chaykin L" first="Louis B." last="Chaykin">Louis B. Chaykin</name>
<affiliation wicri:level="2"><nlm:aff id="Aff3">Meridien Research, Bradenton, FL USA</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Meridien Research, Bradenton</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Courreges, Jean Pierre" sort="Courreges, Jean Pierre" uniqKey="Courreges J" first="Jean-Pierre" last="Courrèges">Jean-Pierre Courrèges</name>
<affiliation wicri:level="3"><nlm:aff id="Aff4">Diabetology and Vascular Disease Unit, General Hospital, Narbonne, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Diabetology and Vascular Disease Unit, General Hospital, Narbonne</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Narbonne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Handelsman, Yehuda" sort="Handelsman, Yehuda" uniqKey="Handelsman Y" first="Yehuda" last="Handelsman">Yehuda Handelsman</name>
<affiliation wicri:level="2"><nlm:aff id="Aff5">Metabolic Institute of America, Tarzana, CA USA</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Metabolic Institute of America, Tarzana</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lehmann, Lucine M" sort="Lehmann, Lucine M" uniqKey="Lehmann L" first="Lucine M." last="Lehmann">Lucine M. Lehmann</name>
<affiliation wicri:level="1"><nlm:aff id="Aff6"><institution-wrap><institution-id institution-id-type="GRID">grid.425956.9</institution-id>
<institution></institution>
<institution>Novo Nordisk A/S,</institution>
</institution-wrap>
Søborg, Denmark</nlm:aff>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Søborg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mishra, Abhishek" sort="Mishra, Abhishek" uniqKey="Mishra A" first="Abhishek" last="Mishra">Abhishek Mishra</name>
<affiliation wicri:level="1"><nlm:aff id="Aff7">Novo Nordisk, Bangalore, India</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Novo Nordisk, Bangalore</wicri:regionArea>
<wicri:noRegion>Bangalore</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Simpson, Richard W" sort="Simpson, Richard W" uniqKey="Simpson R" first="Richard W." last="Simpson">Richard W. Simpson</name>
<affiliation><nlm:aff id="Aff8"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id>
<institution-id institution-id-type="GRID">grid.1002.3</institution-id>
<institution></institution>
<institution>Monash University and Eastern Health,</institution>
</institution-wrap>
Box Hill, VIC Australia</nlm:aff>
<wicri:noCountry code="subfield">VIC Australia</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetes Therapy</title>
<idno type="ISSN">1869-6953</idno>
<idno type="eISSN">1869-6961</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Introduction</title>
<p>The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs.</p>
</sec>
<sec><title>Methods</title>
<p>In this 26-week open-label phase 3b trial, patients on maximum-dose GLP-1RA therapy (liraglutide once daily or exenatide twice daily) with metformin alone or with pioglitazone and/or sulfonylurea were randomized 2:1 to IDegLira once daily (<italic>n</italic>
 = 292) or to unchanged GLP-1RA therapy (<italic>n</italic>
 = 146), continuing OADs at the pre-trial dose.</p>
</sec>
<sec><title>Results</title>
<p>After 26 weeks, HbA<sub>1c</sub>
 reductions were superior with IDegLira versus unchanged GLP-1RA; estimated treatment difference −0.94% (−10.3 mmol/mol), <italic>p</italic>
 < 0.001. Mean HbA<sub>1c</sub>
 reduced from 7.8% to 6.4% (61.5 to 46.9 mmol/mol) with IDegLira and from 7.7 to 7.4% (60.8 to 57.1 mmol/mol) with unchanged GLP-1RA. With IDegLira, 75% and 63% of patients achieved HbA<sub>1c</sub>
 <7% and ≤6.5%, compared with 36% and 23% on unchanged GLP-1RA, respectively. Fasting plasma glucose and 9-point self-monitored blood glucose profiles improved significantly more with IDegLira versus unchanged GLP-1RA. The mean change in weight was +2.0 kg with IDegLira, versus −0.8 kg with unchanged GLP-1RA. Rates of confirmed hypoglycemia were low, but higher with IDegLira versus unchanged GLP-1RA. The safety profile of IDegLira was consistent with previous findings; both treatments were well tolerated and the rate of nausea was low in both groups. IDegLira improved patient-reported outcomes versus unchanged GLP-1RA.</p>
</sec>
<sec><title>Conclusions</title>
<p>IDegLira provided superior glycemic control versus unchanged GLP-1RA and represents an efficacious intensification approach in patients inadequately controlled on GLP-1RAs.</p>
</sec>
<sec><title>Trial registration</title>
<p>ClinicalTrials.gov #NCT01676116.</p>
</sec>
<sec><title>Funding</title>
<p>Novo Nordisk.</p>
</sec>
<sec><title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1007/s13300-016-0218-3) contains supplementary material, which is available to authorized users.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Garber, Aj" uniqKey="Garber A">AJ Garber</name>
</author>
<author><name sortKey="Abrahamson, Mj" uniqKey="Abrahamson M">MJ Abrahamson</name>
</author>
<author><name sortKey="Barzilay, Ji" uniqKey="Barzilay J">JI Barzilay</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Inzucchi, Se" uniqKey="Inzucchi S">SE Inzucchi</name>
</author>
<author><name sortKey="Bergenstal, Rm" uniqKey="Bergenstal R">RM Bergenstal</name>
</author>
<author><name sortKey="Buse, Jb" uniqKey="Buse J">JB Buse</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Nathan, Dm" uniqKey="Nathan D">DM Nathan</name>
</author>
<author><name sortKey="Buse, Jb" uniqKey="Buse J">JB Buse</name>
</author>
<author><name sortKey="Davidson, Mb" uniqKey="Davidson M">MB Davidson</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Eckerle Mize, Dl" uniqKey="Eckerle Mize D">DL Eckerle Mize</name>
</author>
<author><name sortKey="Salehi, M" uniqKey="Salehi M">M Salehi</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Buse, Jb" uniqKey="Buse J">JB Buse</name>
</author>
<author><name sortKey="Bergenstal, Rm" uniqKey="Bergenstal R">RM Bergenstal</name>
</author>
<author><name sortKey="Glass, Lc" uniqKey="Glass L">LC Glass</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Devries, Jh" uniqKey="Devries J">JH DeVries</name>
</author>
<author><name sortKey="Bain, Sc" uniqKey="Bain S">SC Bain</name>
</author>
<author><name sortKey="Rodbard, Hw" uniqKey="Rodbard H">HW Rodbard</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Mathieu, C" uniqKey="Mathieu C">C Mathieu</name>
</author>
<author><name sortKey="Rodbard, Hw" uniqKey="Rodbard H">HW Rodbard</name>
</author>
<author><name sortKey="Cariou, B" uniqKey="Cariou B">B Cariou</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Riddle, Mc" uniqKey="Riddle M">MC Riddle</name>
</author>
<author><name sortKey="Forst, T" uniqKey="Forst T">T Forst</name>
</author>
<author><name sortKey="Aronson, R" uniqKey="Aronson R">R Aronson</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Seino, Y" uniqKey="Seino Y">Y Seino</name>
</author>
<author><name sortKey="Kaneko, S" uniqKey="Kaneko S">S Kaneko</name>
</author>
<author><name sortKey="Fukuda, S" uniqKey="Fukuda S">S Fukuda</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Gough, Sc" uniqKey="Gough S">SC Gough</name>
</author>
<author><name sortKey="Bode, B" uniqKey="Bode B">B Bode</name>
</author>
<author><name sortKey="Woo, V" uniqKey="Woo V">V Woo</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Gough, Sc" uniqKey="Gough S">SC Gough</name>
</author>
<author><name sortKey="Bode, Bw" uniqKey="Bode B">BW Bode</name>
</author>
<author><name sortKey="Woo, Vc" uniqKey="Woo V">VC Woo</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Buse, Jb" uniqKey="Buse J">JB Buse</name>
</author>
<author><name sortKey="Vilsboll, T" uniqKey="Vilsboll T">T Vilsboll</name>
</author>
<author><name sortKey="Thurman, J" uniqKey="Thurman J">J Thurman</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Lingvay, I" uniqKey="Lingvay I">I Lingvay</name>
</author>
<author><name sortKey="Perez Manghi, F" uniqKey="Perez Manghi F">F Perez Manghi</name>
</author>
<author><name sortKey="Garcia Hernandez, P" uniqKey="Garcia Hernandez P">P Garcia-Hernandez</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Brod, M" uniqKey="Brod M">M Brod</name>
</author>
<author><name sortKey="Hammer, M" uniqKey="Hammer M">M Hammer</name>
</author>
<author><name sortKey="Christensen, T" uniqKey="Christensen T">T Christensen</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Brod, M" uniqKey="Brod M">M Brod</name>
</author>
<author><name sortKey="Christensen, T" uniqKey="Christensen T">T Christensen</name>
</author>
<author><name sortKey="Hammer, M" uniqKey="Hammer M">M Hammer</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Garber, Aj" uniqKey="Garber A">AJ Garber</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Holman, Rr" uniqKey="Holman R">RR Holman</name>
</author>
<author><name sortKey="Thorne, Ki" uniqKey="Thorne K">KI Thorne</name>
</author>
<author><name sortKey="Farmer, Aj" uniqKey="Farmer A">AJ Farmer</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Aroda, Vr" uniqKey="Aroda V">VR Aroda</name>
</author>
<author><name sortKey="Bailey, Ts" uniqKey="Bailey T">TS Bailey</name>
</author>
<author><name sortKey="Cariou, B" uniqKey="Cariou B">B Cariou</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Philis Tsimikas, A" uniqKey="Philis Tsimikas A">A Philis-Tsimikas</name>
</author>
<author><name sortKey="Del, Ps" uniqKey="Del P">PS Del</name>
</author>
<author><name sortKey="Satman, I" uniqKey="Satman I">I Satman</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rodbard, Hw" uniqKey="Rodbard H">HW Rodbard</name>
</author>
<author><name sortKey="Cariou, B" uniqKey="Cariou B">B Cariou</name>
</author>
<author><name sortKey="Zinman, B" uniqKey="Zinman B">B Zinman</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Swinnen, Sg" uniqKey="Swinnen S">SG Swinnen</name>
</author>
<author><name sortKey="Dain, Mp" uniqKey="Dain M">MP Dain</name>
</author>
<author><name sortKey="Mauricio, D" uniqKey="Mauricio D">D Mauricio</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Simpson, R" uniqKey="Simpson R">R Simpson</name>
</author>
<author><name sortKey="King, A" uniqKey="King A">A King</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004015 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004015 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:5306117
   |texte=   The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:27943107" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki